Rapid clinical deployment of <i>UBA1</i> testing in patients with VEXAS syndrome
A cost-effective, mass spectrometry-based assay with high analytical and clinical performance can feasibly be implemented in hospital laboratories for diagnosis of VEXAS syndrome.
Authors
- Lauren Lawrence (ORCID: https://orcid.org/0000-0002-3405-4571)
- David B. Beck (ORCID: https://orcid.org/0000-0002-5884-6231)
- Paul A. Wadsworth (ORCID: https://orcid.org/0000-0002-4562-7830)
- Jasmin Le
- Chandler Ho (ORCID: https://orcid.org/0009-0006-0035-058X)
- Carlos J. Suarez (ORCID: https://orcid.org/0000-0002-4531-9723)
- Marcela A. Ferrada (ORCID: https://orcid.org/0000-0003-3256-3273)
- Peter C. Grayson (ORCID: https://orcid.org/0000-0002-8269-9438)
- Simon Chen (ORCID: https://orcid.org/0000-0003-0409-5978)
- Paolo Libiran
Institutions
- University of Maryland, Baltimore (US)
- National Institutes of Health (US)
- University of Maryland Medical Center (US)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (US)
- Guardant (United States) (US)
- Stanford Health Care (US)
- New York University (US)
- University of Pennsylvania (US)
- Stanford University (US)
Publication Details
- Journal
- American Journal of Clinical Pathology
- Published
- 2025-05-08
- DOI
- https://doi.org/10.1093/ajcp/aqaf051
- Citations
- 1
- Primary Topic
- Otitis Media and Relapsing Polychondritis
- Type
- article
- Field-Weighted Citation Impact
- 1.67